Thursday September 21
San Diego USA

2016 Finalists

The 2016 World ADC Awards finalists are:

Individual Input to the Field 2015/2016

  • Aldo Braca, BSP Pharmaceuticals
  • David Thurston, King’s College London, FemtoGenix
  • Scott Dylla, Stemcentrx
  • Thomas Pillow, Genentech
  • Xavier Depinoy, Piramal

Best New Drug Developer 

  • ADC Therpaeutics
  • CytomX
  • Formation Biologics
  • Ganymed
  • Mersana

Supported by: Pfizer

Most Promising Clinical Candidate

  • ADCT-301, ADC Therapeutics
  • ADDV-399, AbbVie
  • Glembatumumab Vedotin, Celldex
  • MEDI4276, MedImmune
  • Rovalpituzumab Tesirine, Stemcentrx

Best ADC Platform Technology

  • Catalent – SMARTag
  • Bicycle Therapeutics – Bicycles®
  • Innate Pharma – Transglutaminase conjugation
  • NBE Therapeutics – SMAC™-Technology
  • Mersana – Fleximer

Best Contract Manufacturing (CMO) Provider 

  • BSP Pharmaceuticals
  • Lonza
  • Novasep
  • Pierre Fabre
  • Piramal

Best Contract Research (CRO) Provider 

  • Chemistry Research Solutions (Abzena)
  • Covance
  • Eurofins Lancaster
  • Menarini
  • Quality Assistance

Best Publication 2015

  • Saunders et al., A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med., 2015.
  • van Geel et al., Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N‑Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody−Drug Conjugates; Bioconj. Chem., 2015.
  • Lehar et al., Novel antibody–antibiotic conjugate eliminates intracellular S. aureus ; Nature, 2015

Best Poster

Supported by: abbvie